Clinical Trial Update: A Randomized, Double-Blinded, Placebo-Controlled, Two-Way Crossover Study to Investigate the Safety and Toleration of Single Dose Sildenafil in Subjects Receiving Chronic UK-369,0031 [Phase 1]

View source ↗

Summary

This Phase 1 trial is a randomized, double-blind, placebo-controlled two-way crossover study to assess the safety and tolerability of a single dose of sildenafi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Benign Prostatic Hyperplasia
• Erectile Dysfunction
• Overactive Bladder

Drugs mentioned

• SILDENAFIL (SILDENAFIL)
• UK-369,0031 (UK-369-0031)

Snippet

Sponsor: Pfizer | Conditions: Prostatic Hyperplasia, Urinary Bladder, Overactive | Phase 1 | Status: COMPLETED